Epidemiological characteristics and access to end-stage liver disease care for HIV-positive patients with HCV and/or HBV coinfections in Central/Eastern European and neighboring countries – data from the ECEE network


Journal

Przeglad epidemiologiczny
ISSN: 0033-2100
Titre abrégé: Przegl Epidemiol
Pays: Poland
ID NLM: 0413725

Informations de publication

Date de publication:
2019
Historique:
entrez: 29 5 2019
pubmed: 28 5 2019
medline: 28 12 2019
Statut: ppublish

Résumé

There is currently an urgent need to harmonize hepatitis standards of care for HIV-positive patients across Europe. The HIV epidemic in Central and Eastern Europe has often been driven by injecting drug use, therefore a higher rate of co-infection with HCV and HBV is expected in this region. We have investigated the epidemiological prevalence and treatment availability for end-stage liver disease in HIV/HCV/HBV coinfections in countries represented in the ECEE Network Group. The Euroguidelines in Central and Eastern Europe (ECEE) Network Group was initiated in February 2016 to compare standards of care regarding HIV infection in the region. Information about HIV/HCV/HBV co-infections and the availability for end-stage liver disease treatment for HIV-positive patients were collected through on-line surveys. The respondents were ECEE members from 16 countries of the region. The information on co-infection prevalence was sourced from WHO, national HIV programmes, articles published in international journals, single clinic reports, and personal information in ten of the participating countries (62.5%). The HIV/HCV co-infection rate was from 3% to 99%. The range of reported of HIV/HBV coinfection percentages was 2.3% to 40%. HIV/HCV/HBV co-infection ranged from 0% to 9%. Regarding treatment for end-stage liver disease, liver transplantation was an available option for HIV-positive patients in only three countries (19%). Our findings revealed only a limited number of treatment options for the end-stage liver disease in HIV-positive patients for the vast majority of Central and Eastern European countries. There are gaps in epidemiological surveillance in this region. It appears there are many differences in the number of co-infected patients among Central and Eastern European and neighboring countries, but there is no unification of information sources.

Identifiants

pubmed: 31134775
doi: 10.32394/pe.73.07

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-68

Auteurs

Agata Skrzat-Klapaczyńska (A)

Hospital for Infectious Diseases, Warsaw
Medical University of Warsaw, Department for Adult’s Infectious Diseases, Warsaw, Poland

Bartłomiej Matłosz (B)

Hospital for Infectious Diseases, HIV Out-Patient Clinic, Warsaw, Poland

Dan Otelea (D)

National Institute for Infectious Diseases, Bucharest, Romania

Arjan Harxhi (A)

Department of Infectious Disease, Faculty of Medicine, University Hospital Center of Tirana, Albania

Anna Vassilenko (A)

Belarusian State Medical University, Minsk, Belarus

Natalia Bolokadze (N)

Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia

Kristi Rüütel (K)

Department of Drug and Infectious Diseases Epidemiology, Tallinn, Estonia

Antonios Papadopoulos (A)

Medical School - National and Kapodistrian University of Athens, University General Hospital “ATTIKON”, Athens, Greece

Mariana Mardarescu (M)

Pediatric Department, National Institute for Infectious Diseases “Prof Dr Matei Balş”, Bucharest, Romania

Mike Youle (M)

Department of HIV Medicine, Royal Free London Hospital, London, UK

Justyns D. Kowalska (JD)

Hospital for Infectious Diseases, Warsaw
Medical University of Warsaw, Department for Adult’s Infectious Diseases, Warsaw, Poland

Aandrzej Horban (A)

Hospital for Infectious Diseases, Warsaw
Medical University of Warsaw, Department for Adult’s Infectious Diseases, Warsaw, Poland

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH